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Abstract 
Acetaminophen is widely used as a common analgesic agent, but toxic liver injury is a 
well known side effect of acetaminophen when used long-term. Compared to the 
clinical doses of acetaminophen used in Western countries and in China, the clinical 
doses used in Japan have been lower, and the drug potency is not high. The clinical 
doses of acetaminophen in Japan were increased in 2011, but the incidence of toxic liver 
injury remains to be investigated. In this study, the pharmacokinetics of acetaminophen 
were compared between Chinese and Japanese subjects, given that both are Asians and 
acetaminophen has been prescribed at high doses with an average of approximately 
1,000 mg for many years in both countries. A single oral dose of acetaminophen 1,000 
mg was administered to healthy Japanese and Chinese volunteers (8 participants each), 
and the pharmacokinetic parameters and urinary excretion rates were measured. No 
differences in pharmacokinetics of acetaminophen were observed between Japanese and 
Chinese subjects, and no differences in 24-h urinary excretion rates of unchanged 
acetaminophen and acetaminophen glucuronide as well as 4-acetaminophen sulfate and 
3-cysteinyl acetaminophen were found. The pharmacokinetics of acetaminophen were 
similar in Chinese and Japanese subjects, and the risk of developing drug-induced toxic 
liver injury associated with an increase in acetaminophen dose is predicted to be 
comparable in the two ethnic groups.  
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Introduction 
 
Acetaminophen is a widely used common analgesic, although the development of toxic 
liver injury is a well known side effect when used long-term 
1)
. Ingested acetaminophen 
follows a metabolic pathway in which approximately 85% of the drug is subjected to in 
vivo glucuronidation by uridine diphosphate-glucuronosyltransferase (UGT), especially 
by UGT1A6, and sulfoconjugation by sulfotransferase (SULT)1A1 and SULT1A3. In 
addition, approximately 8–10% undergoes oxidation by cytochrome P-450(CYP)2El 2, 3). 
Particularly, N-acetyl-p-benzo-quinone imine (NAPQI), which is an intermediate 
metabolite produced by metabolism of CYP2El, has been reported to be a major cause 
of drug-induced liver injury (DILI) 
4-6)
. Excessive production of NAPQI because of a 
high level of chemical reactivity causes a depletion in glutathione (GSH) and strong 
binding with proteins, leading to cell death, thereby resulting in the development of 
DILI. Development of toxic DILI due to acetaminophen depends on the NAPQI 
generated through this series of metabolic activities, and may also depend on exposure. 
These could also be explained by data showing that toxic DILI often develops in heavy 
drinkers with induced CYP2E1 
7)
. 
The clinical doses of acetaminophen used in Japan have been lower than those used in 
Western countries and in China, and are considered to be effective. In 2011, the clinical 
doses in Japan were increased from a maximum of 300 mg per dose and a maximum 
dosage of 1,500 mg per day to a maximum of 1,000 mg per dose and a maximum 
dosage of 4,000 mg per day 
2)
. However, the possibility of increase in risk of toxic DILI 
requires investigation. Ethnic differences in pharmacokinetics have been reported
 8, 9)
, 
but no previous studies have compared the pharmacokinetics of acetaminophen and the 
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above-mentioned series of metabolism between Japanese subjects and other ethnic 
groups. The Rumack-Matthew nomogram could be used to prognosticate the severity of 
possible liver toxicity after ingestion of acetaminophen
10, 11)
, but the development of 
DILI due to acetaminophen is dose-dependent and understanding the pharmacokinetics 
of acetaminophen is necessary. If the pharmacokinetics of acetaminophen in Japanese 
subjects show higher Cmax and AUC compared to other ethnic groups, the risk of DILI 
may also be higher. A previous study reported that the safety of high doses of 
acetaminophen does not differ between non-Japanese Asian and Western subjects
12)
. In 
the present study, we compared the pharmacokinetics of acetaminophen between 
Chinese and Japanese subjects. We compared these two ethnic groups because both are 
Asians and acetaminophen has been prescribed at high dosages to Chinese subjects with 
an average of approximately 1,000 mg for many years. We also estimated the predicted 
frequency of DILI due to administration of high doses of acetaminophen. 
 
Methods 
 
Participants 
Sixteen healthy male volunteers aged ≥ 20 years but < 40 years (8 Japanese and 8 
Chinese subjects) participated in this study. All subjects signed a written informed 
consent for participating in the study. In all participants, eligibility to participate in the 
study was determined by a screening test conducted by the physician in charge of the 
study. Subjects were excluded if they had a past history of anaphylaxis due to 
acetaminophen, peptic ulcer, blood abnormality or heavy alcohol consumption. 
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Study Design 
This study was not blinded and examined a single oral dose of acetaminophen. 
 
Drug Administration 
For one week before the screening and one week before the study, as well as during the 
testing period, excessive physical exercise was forbidden in order to avoid possible 
impact on blood test results. On the day of study, the participants were administered a 
single oral dose of 1,000 mg of acetaminophen. Considering the possible effects on drug 
absorption, the participants were instructed to refrain from reclining in a supine position 
for 4 h after drug administration. The dose was determined taking into account the fact 
that the maximum dosage of acetaminophen in Japan was 200-500 mg per dose and 
1,500 mg per day, while the maximum dosage in China was 600 mg per dose and 2,000 
mg per day. From two weeks before oral administration of the test drug until discharge 
from the hospital, the participants were discouraged from using medications including 
nonprescription drugs, prescription drugs, Kampo drugs, and transdermal patches with 
systemic effects. They were also discouraged from taking health foods containing St. 
John's Wort, unless the physician in charge of the study considered it necessary to use 
the foods, and unless the foods had no effect on pharmacokinetics. Ingestion of food and 
drinks was prohibited starting from 0 hour on the day of oral intake of the study drug, 
and drinking water was forbidden for a 4-h period starting from the time of 
administration of the drug, except during oral intake of the medication. In addition, food 
and drinks containing grapefruit, orange, and apple; alcohol-containing beverages; 
caffeine-containing beverages; and tobacco were also prohibited. 
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Sample collection and processing, and analysis of the evaluation items 
Table 1 shows the time schedule used in this study. Approximately 7 mL of blood was 
collected immediately after drug administration, as well as at 15 min, 30 min, 1 h, 1.5 h, 
2 h, 4 h, 6 h, 8 h, 10 h, and 12 h after drug administration. The samples were 
immediately cooled with ice and centrifuged (4°C, 3,000 rpm, 10 min), and plasma was 
then separated. The plasma samples were stored frozen at -70°C or below until 
measurement of plasma drug levels. Urine was collected before administration of 
acetaminophen, as well as 0–4, 4–12, and 12–24 h after administration of 
acetaminophen. Urine was harvested in a urine collection container, which was treated 
with ascorbic acid. The urine samples were stored in a cool and dark place and were 
sufficiently mixed. The total volume was then measured. Some of the collected urine 
was stored frozen at -70°C or below until measurement of drug concentrations. 
 
Measurement of drug concentrations in plasma and urine and pharmacokinetic 
analysis 
The plasma and urinary levels of acetaminophen and acetaminophen glucuronide, 
4-acetaminophen sulfate, 3-cysteinyl acetaminophen (a metabolite of NAPQI), and 
acetaminophen mercapturate were measured using LC/MC/MS methods 
13, 14)
. All 
specimens were measured at Shin Nippon Biomedical Laboratories, Ltd., Japan. All 
participants who were administered acetaminophen were analyzed. The 
pharmacokinetic parameters comprising Cmax, Tmax, AUC0-12, and elimination 
half-life (T1/2) were calculated by WinNonlin (Pharsight Corporation, USA) using a 
noncompartmental model. 
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Statistics 
All results were analyzed using JMP version 11.0 (SAS Institute Inc). Characteristic 
data and all pharmacokinetic parameters data were expressed as mean with standard 
deviation. These data were analyzed using Student’s t-test. 
   
Safety assessment 
To evaluate participants' safety, subjective and objective symptoms were observed, 
physical examinations were performed, and electrocardiography and clinical laboratory 
tests were also performed after administration of acetaminophen. 
 
Ethical considerations 
The study protocol was approved by Kitasato University Medical Ethics Organization 
(KMEO) B10-30, G10-15. This study has been registered at the University Hospital 
Medical Information Network Clinical Trials Registry (UMIN-CTR; No. 
UMIN000003637). During preparation of case reports and handling of participants' data, 
the privacy of the participants was taken into consideration and confidentiality was 
maintained using participant identification codes instead of the initials of the 
participants' names. This also applied to participants who only underwent screening. 
 
Results 
 
Participant information  
Of the16 study participants, 8 were Japanese and 8 were Chinese subjects. The 
participants from each country were registered at the Kitasato University East Hospital 
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Clinical Trial Management Center, and none of the participants dropped out until the 
end of the study.  
No significant differences were found between the Japanese and Chinese participants 
with respect to age (30.3 ± 6.3 vs. 27.1 ± 3.3 years, p = 0.236), height (172.1 ± 7.2 vs. 
173.9 ± 7.8 cm, p = 0.635), and body weight (69.1 ± 11.9 vs. 67.2 ± 9.3 kg, p = 0.739). 
 
Pharmacokinetic parameters 
The plasma levels of acetaminophen increased rapidly after administration of the dose. 
Since almost no acetaminophen mercapturate was detected in plasma, analysis of this 
compound was not possible. There were no significant differences between Japanese 
and Chinese subjects in all the pharmacokinetic parameters including AUC0-12, Cmax, 
Tmax and t1/2 (Table 3, Figures 1–4). There were no significant differences in urinary 
excretion rates of acetaminophen and all metabolites between Japanese and Chinese 
subjects (Table 4). 
 
Safety evaluation 
In terms of adverse events, among the 8 Chinese subjects who were administered 
acetaminophen, two participants developed internal bleeding in the left cubital fossa, 
and two other participants developed a nasal discharge. However, the events were mild 
and appeared to be unrelated to the test drug. No adverse events were observed in the 8 
Japanese subjects. 
 
Discussion 
In this study, comparisons were carried out to determine whether the pharmacokinetics 
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of acetaminophen differed between Japanese and Chinese subjects. For this purpose, 
Japanese and Chinese healthy volunteers were administered a single oral dose of 
acetaminophen, and the pharmacokinetics in each ethnic group were evaluated. No 
differences in age, body weight, and stature were found between the Japanese and 
Chinese subjects who participated in this study. According to a report published by the 
Ministry of Health, Labor, and Welfare in 2011, Japanese subjects aged between 18 and 
29 years had a mean height of 170.8 cm and mean body weight of 65.4 kg 
15)
, and 
according to a report published by the General Administration of Sport of China in 2011, 
Chinese subjects aged between 25 and 29 years had a mean height of 170.7 cm and 
mean body weight of 68.7 kg 
16)
. The Japanese participants in our study had a mean 
height of 171.9 ± 7.2 cm and mean body weight of 68.2 ± 11.9 kg, while the Chinese 
participants had a mean height of 173.7 ± 7.8 cm and mean body weight of 66.7 ± 9.3 
kg. Therefore, the participants in our study were considered to have an average 
physique for Japanese and Chinese.  
In terms of unchanged acetaminophen, acetaminophen glucuronide, 4-acetaminophen 
sulfate, and 3-cysteinyl acetaminophen levels, the pharmacokinetic parameters of 
acetaminophen were comparable in Japanese and Chinese subjects. Similar to the 
pharmacokinetic parameters, the urinary excretion rates of unchanged acetaminophen 
and its metabolites were also not different between Japanese and Chinese subjects. 
The activity of UGT1A6 that catalyzes glucuronide conjugation of acetaminophen has 
been reported to be different between Westerners and Asians. However, Pei-Chieng et al. 
17)
 found no difference in UGT1A6 activity evaluated by expression of single-nucleotide 
polymorphisms (SNP) between Japanese and Chinese subjects, who are both East 
Asians. This is consistent with our result of no difference in metabolism of 
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acetaminophen glucuronide between Japanese and Chinese subjects. Similar to the 
finding of UGT1A6, previous reports have also indicated no difference between 
Japanese and Chinese subjects with respect to SULT, which is an enzyme that catalyzes 
sulfate conjugation of acetaminophen. This finding is consistent with the result in the 
present study showing no difference in metabolism of acetaminophen sulfate between 
Japanese and Chinese subjects. As for CYP2E1, an enzyme that metabolizes 
acetaminophen to NAPQ and is considered to be the cause of DILI due to 
acetaminophen, slight differences in SNP have been reported between Japanese and 
Chinese subjects. However, in our study, the metabolism of 3-cysteinyl acetaminophen 
was not different between Japanese and Chinese subjects. Further, a lack of difference 
in physique, which is believed to have a significant impact on the blood levels of 
acetaminophen, may be one of the reasons for the absence of differences between 
Japanese and Chinese subjects in terms of the pharmacokinetic parameters of 
acetaminophen. 
The results of previous clinical studies using intravenous formulation of acetaminophen 
in Japanese subjects and clinical studies using intravenous formulation of 
acetaminophen in Westerners 
18)
 have shown that Cmax and AUC tend to be slightly 
higher in Japanese than in Westerners. This result suggests that Japanese may be at 
higher risk of DILI than Westerners. High level of exposure is especially noted in 
Japanese subjects following increase of the approved dose. The risk of liver injury 
increases especially in cases where nonlinear pharmacokinetics is observed. However, 
the results of our previous study
19)
 revealed linear pharmacokinetics of oral 
acetaminophen at doses of 300 mg, 600 mg, and 1,000 mg. Moreover, in a previous 
study conducted in Japan
 20)
, patients with diseases or conditions such as osteoarthritis, 
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cancer pain, and lower back pain were administered acetaminophen at doses of 2,400–
4,000 mg/day. As a result, 7 of the 332 patients (approximately 2.1%) showed ALT 
levels three times higher than the reference values, and a causal relationship could not 
be ruled out in 3 of the patients (0.9%). 
In a study reported by Kuffner et al. 
21)
, in which 1,039 osteoarthritis patients were 
administered 1,950–4,000 mg acetaminophen, ALT levels three times higher than the 
reference values were observed in 10 patients (approximately 1.0%), and causality 
could not be ruled out in 7 cases (approximately 0.7%). These results show similar 
tendencies to those found in previous studies conducted in Japan, and also suggest no 
significant difference in impact of large doses of acetaminophen on the occurrence of 
DILI between Westerners and Japanese, despite the physical differences between the 
two ethnic groups. To the best of our knowledge, no previous report had shown that 
severe DILI due to acetaminophen was more frequent in Chinese than in other ethnic 
groups. The absence of differences in pharmacokinetics for acetaminophen between 
Japanese and Chinese subjects, as shown in our study, also suggests that 
pharmacokinetically, administration of high doses of acetaminophen to Japanese 
subjects has no marked effect on the occurrence of DILI, compared to other ethnic 
groups. 
 
Conclusions 
The findings of this study indicate that the pharmacokinetics of acetaminophen are 
similar in Chinese and Japanese subjects, and that the risk of developing toxic DILI 
associated with an increase in dosage of acetaminophen may be predicted to be 
comparable in the two ethnic groups. 
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Table1 Time schedule 
 
  
Day 2
Pre
Administration
0hr 15min 30min 1hr 1.5hr 2hr 3hr 4hr 6hr 8hr 10hr 12hr 24hr
○
○ Hospitalization Leaving Revisit
○
○
○
○ ○ ○ ○
○ ○ ○
○ ○ ○ ○ ○ ○ ○ ○ ○
Laboratory tests ○ ○ ○ ○
HBs antigen、HCV antibody、HIV antigen/antibody
TP antibody（3ml/a time）
○
Pharmacokinetics ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
Urinalysis ○ ○ ○ ○ ○
Pharmacokinetics ○
○ ○
Laboratory tests 13 8 10 10 8
Pharmacokinetics （ml/a time） 7 7 7 7 7 7 7 7 7 7 7
Pharmacogenomics 5
Subsequent
examination
Day 1
Body weight
Subjective and objective symptoms
Body temperture, Blood pressure and Pulse
Obtainment of informed consent
Hospital visiting
Meal and drink (water)
Oral administration (single-dose 1000mg)
Height
Amount of drawn blood
Screening Day -1
Blood sampling
Urine sampling
Electrocardiograghy (ECG)
No food or drink
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Table2 Summary of pharmacokinetic parameters of acetaminophen (1,000mg) in 
Japanese (n=8) and Chinese (n=8) subjects 
 
  
Pharmacokinetic parameter
 Tmax, hr 0.38 ± 0.13 0.41 ± 0.13 p  = 0.642 2.19 ± 0.75 1.88 ± 0.23 p  = 0.281
 Cmax, μg/mL 18.8 ± 5.88 16.3 ± 4.1 p  = 0.341 21.56 ± 7.34 20.52 ± 6.02 p  = 0.763
 AUC0-12, μg・h/mL 55.8 ± 11.94 56.2 ± 10.7 p  = 0.955 136.5 ± 32.1 130.2 ± 34.6 p  = 0.710
 T1/2, hr 2.66 ± 0.38 2.9 ± 0.37 p  = 0.172 3.04 ± 0.26 3.1 ± 0.22 p = 0.637
Pharmacokinetic parameter
 Tmax, hr 1.25 ± 0.27 1.37 ± 0.23 p  = 0.334 4.0 ± 1.07 4.0 ± 0 p  = 1.000
 Cmax, μg/mL 7.18 ± 1.64 6.95 ± 1.18 p  = 0.754 0.49 ± 0.13 0.5 ± 0.28 p  = 0.888
 AUC0-12, μg・h/mL 43.3 ± 12.3 42.0 ± 10.5 p  = 0.825 3.73 ± 1.2 3.63 ± 2.1 p  = 0.911
 T1/2, hr 2.99 ± 0.21 3.13 ± 0.2 p  = 0.206 4.05 ± 1.17 4.04 ± 0.41 p  = 0.988
Acetaminophen Acetaminophen glucuronide
Japanese subjects vs Chinese (Han-people) subjects
Japanese subjects vs Chinese (Han-people) subjects
 4-Acetaminophen sulfate 3-Cysteinyl Acetaminophen
Values are means ±standard deviation
The data were analyzed by t test
Tmax, Time to Maximum plasma concentration; Cmax, Maximum plasma concentration; AUC0-12, Area under the plasma concentration-
time; T1/2, Terminal elimination half-life
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Figure1 Time course of plasma acetaminophen concentration following a single dose of 
acetaminophen 1,000mg in Chinese and Japanese healthy male subjects 
The concentrations of metabolites were calculated as APAP equivalents. 
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Figure2 Time course of plasma acetaminophen glucuronide concentration following a 
single dose of acetaminophen 1,000mg in Chinese and Japanese healthy male subjects 
The concentrations of metabolites were calculated as APAP equivalents. 
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Figure3 Time course of plasma 4-acetaminophen sulfate concentration following a 
single dose of acetaminophen 1,000mg in Chinese and Japanese healthy male subjects 
The concentrations of metabolites were calculated as APAP equivalents. 
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Figure4 Time course of plasma 3-cysteinyl acetaminophen concentration following a 
single dose of acetaminophen 1,000mg in Chinese and Japanese healthy male subjects 
The concentrations of metabolites were calculated as APAP equivalents.  
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Table 3 Cumulative amount of drug excreted in urine (% of dose) 
 
Japanese subjects (n=8) Chinese (Han-people) subjects (n=8) P  value
Acetaminophen 2.1 ± 0.8 2.3 ± 0.8 p  = 0.519
Acetaminophen glucuronide 49.8 ± 9.9 51.9 ± 12.5 p  = 0.722
 4-Acetaminophen sulfate 28.1 ± 8.5 25.7 ± 3.40 p  = 0.498
3-Cysteinyl Acetaminophen 3.77 ± 1.72 3.92 ± 3.01 p  = 0.904
Acetaminophen mercapturate 1.01 ± 0.52 1.31 ± 1.23 p  = 0.536
Total 84.6 ± 7.62 85.1 ± 9.13 p  = 0.893
Values are means ±standard deviation
The data were analyzed by t test
